U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
U.S. Announces Additional $6 Million in Humanitarian Aid to Cuba Amid Oil Sanctions and Fuel Shortages
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
China Warns US Arms Sales to Taiwan Could Disrupt Trump’s Planned Visit
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding 



